Brought to you by 
Antisoma licenses pemtumomab to Abbott, later opts out
22 Nov 2002
Executive Summary
Abbott Laboratories has licensed worldwide exclusive development and marketing rights from UK cancer biopharmaceutical company Antisoma to its late-stage ovarian cancer drug candidate Theragyn. The deal is potentially worth $110mm, mostly from milestones.
Deal Industry
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Antisoma licenses pemtumomab to Abbott, later opts out
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice